SUNAMERICA STRATEGIC INVESTMENT SERIES, INC. (R)
SUNAMERICA BIOTECH/HEALTH 30 FUND
Supplement to the Prospectus dated June 14, 2000
Under the section entitled "SALES CHARGE REDUCTIONS AND
WAIVERS - WAIVERS FOR CERTAIN INVESTORS" - on page 6 of the
Prospectus, the following should be added after the first
paragraph:
We will generally waive the front-end sales charge for
Class II shares purchased through certain financial
intermediaries that maintain omnibus accounts and have executed
an agreement with the Distributor to sell Class II shares with no
front-end sales charge.
Dated: December 1, 2000
